Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review-Reference-Cited by-同舟云学术

Effect and safety of dual anti-human epidermal growth factor receptor 2 therapy compared to monotherapy in patients with human epidermal growth factor receptor 2-positive breast cancer: a systematic review

Published:2014-08-28 Issue:1 Volume:14 Page:
ISSN:1471-2407
Container-title:BMC Cancer
language:en
Short-container-title:BMC Cancer

Author:

Zhang Xiao,Zhang Xin-Ji,Zhang Tian-Yi,Yu Fei-Fei,Wei Xin,Li Ye-Sheng,He Jia

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Genetics,Oncology

Link

http://link.springer.com/content/pdf/10.1186/1471-2407-14-625.pdf

Reference30 articles.

1. Brollo J, Curigliano G, Disalvatore D, Marrone BF, Criscitiello C, Bagnardi V, Kneubil MC, Fumagalli L, Locatelli M, Manunta S, Goldhirsch A: Adjuvant trastuzumab in elderly with HER-2 positive breast cancer: a systematic review of randomized controlled trials. Cancer Treat Rev. 2013, 39 (1): 44-50.

2. Patani N, Mokbel K: Herceptin and breast cancer: an overview for surgeons. Surg Oncol. 2010, 19 (1): e11-e21.

3. Binns C, Low WY, Lee MK: Breast cancer: an increasing public health problem in the Asia pacific region. Asia Pac J Public Health. 2013, 25 (5): 364-367.

4. Ross JS, Slodkowska EA, Symmans WF, Pusztai L, Ravdin PM, Hortobagyi GN: The HER-2 receptor and breast cancer: ten years of targeted anti-HER-2 therapy and personalized medicine. Oncologist. 2009, 14 (4): 320-368.

5. Vogel UF: Confirmation of a low HER2 positivity rate of breast carcinomas - limitations of immunohistochemistry and in situ hybridization. Diagn Pathol. 2010, 5: 50-

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Pertuzumab combined with trastuzumab compared to trastuzumab in the treatment of HER2-positive breast cancer: A systematic review and meta-analysis of randomized controlled trials;Frontiers in Oncology;2022-09-28

2. Non-pharmacological interventions for postpartum depression;Medicine;2020-07-31

3. Cost-Effectiveness Analysis of Pertuzumab With Trastuzumab and Chemotherapy Compared to Trastuzumab and Chemotherapy in the Adjuvant Treatment of HER2-Positive Breast Cancer in the United States;Value in Health;2019-04

4. Network Propagation Predicts Drug Synergy in Cancers;Cancer Research;2018-07-27

5. Bringing 3D tumor models to the clinic - predictive value for personalized medicine;Biotechnology Journal;2017-01-18